NICE (The National Institute for Health and Clinical Excellence) has begun its appraisal of Gilenya® (fingolimod), a new oral medication for relapsing-remitting Multiple Sclerosis.
Fingolimod was granted a licence by the EMA (European Medicines Agency) in March 2011. The appraisal by NICE is to decide whether it should be funded by the NHS.
Gilenya® (fingolimod) is the first in a new class of disease-modifying treatments called sphingosine 1-phosphate receptor (S1P-R) modulators and has a novel mode of action different from all currently marketed MS therapies.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309